These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 22415521)

  • 1. Pathologic polyglutamine aggregation begins with a self-poisoning polymer crystal.
    Kandola T; Venkatesan S; Zhang J; Lerbakken BT; Von Schulze A; Blanck JF; Wu J; Unruh JR; Berry P; Lange JJ; Box AC; Cook M; Sagui C; Halfmann R
    Elife; 2023 Nov; 12():. PubMed ID: 37921648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flanking sequences profoundly alter polyglutamine toxicity in yeast.
    Duennwald ML; Jagadish S; Muchowski PJ; Lindquist S
    Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11045-50. PubMed ID: 16832050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A network of protein interactions determines polyglutamine toxicity.
    Duennwald ML; Jagadish S; Giorgini F; Muchowski PJ; Lindquist S
    Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11051-6. PubMed ID: 16832049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAG Expansions Are Genetically Stable and Form Nontoxic Aggregates in Cells Lacking Endogenous Polyglutamine Proteins.
    Zurawel AA; Kabeche R; DiGregorio SE; Deng L; Menon KM; Opalko H; Duennwald ML; Moseley JB; Supattapone S
    mBio; 2016 Sep; 7(5):. PubMed ID: 27677791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets.
    Costa MD; Maciel P
    Cell Mol Life Sci; 2022 May; 79(5):274. PubMed ID: 35503478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggregation of expanded polyglutamine domain in yeast leads to defects in endocytosis.
    Meriin AB; Zhang X; Miliaras NB; Kazantsev A; Chernoff YO; McCaffery JM; Wendland B; Sherman MY
    Mol Cell Biol; 2003 Nov; 23(21):7554-65. PubMed ID: 14560003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.
    Popiel HA; Takeuchi T; Burke JR; Strittmatter WJ; Toda T; Wada K; Nagai Y
    Neurotherapeutics; 2013 Jul; 10(3):440-6. PubMed ID: 23504628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disrupted nuclear import of cell cycle proteins in Huntington's/PolyQ disease causes neurodevelopment defects in cellular and Drosophila model.
    Dubey SK; Lloyd TE; Tapadia MG
    Heliyon; 2024 Feb; 10(4):e26393. PubMed ID: 38434042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.
    Popiel HA; Burke JR; Strittmatter WJ; Oishi S; Fujii N; Takeuchi T; Toda T; Wada K; Nagai Y
    J Amino Acids; 2011; 2011():265084. PubMed ID: 22312459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photocontrol of the β-Hairpin Polypeptide Structure through an Optimized Azobenzene-Based Amino Acid Analogue.
    Parlato R; Volarić J; Lasorsa A; Bagherpoor Helabad M; Kobauri P; Jain G; Miettinen MS; Feringa BL; Szymanski W; van der Wel PCA
    J Am Chem Soc; 2024 Jan; 146(3):2062-2071. PubMed ID: 38226790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic polyglutamine aggregation begins with a self-poisoning polymer crystal.
    Kandola T; Venkatesan S; Zhang J; Lerbakken B; Schulze AV; Blanck JF; Wu J; Unruh J; Berry P; Lange JJ; Box A; Cook M; Sagui C; Halfmann R
    bioRxiv; 2023 Jul; ():. PubMed ID: 36993401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Protein Quantity Control in Polyglutamine Spinocerebellar Ataxias.
    Zhang H; Wang X
    Cerebellum; 2024 Jul; ():. PubMed ID: 39052145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular therapy for polyQ disorders: from bench to clinical trials.
    de Sousa-Lourenço J; Silva AC; Pereira de Almeida L; Nobre RJ
    Trends Mol Med; 2024 Jun; ():. PubMed ID: 38839514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Author Correction: Amyloid modifier SERF1a interacts with polyQ-expanded huntingtin-exon 1 via helical interactions and exacerbates polyQ-induced toxicity.
    Tsai TY; Chen CY; Lin TW; Lin TC; Chiu FL; Shih O; Chang MY; Lin YC; Su AC; Chen CM; Jeng US; Kuo HC; Chang CF; Chen YR
    Commun Biol; 2024 May; 7(1):601. PubMed ID: 38762602
    [No Abstract]   [Full Text] [Related]  

  • 15. Author Correction: Amyloid modifier SERF1a interacts with polyQ-expanded huntingtin-exon 1 via helical interactions and exacerbates polyQ-induced toxicity.
    Tsai TY; Chen CY; Lin TW; Lin TC; Chiu FL; Shih O; Chang MY; Lin YC; Su AC; Chen CM; Jeng US; Kuo HC; Chang CF; Chen YR
    Commun Biol; 2023 Oct; 6(1):1021. PubMed ID: 37814125
    [No Abstract]   [Full Text] [Related]  

  • 16. Using yeasts for the studies of nonfunctional factors in protein evolution.
    Potera K; Tomala K
    Yeast; 2024 Jun; ():. PubMed ID: 38895906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Liquid to Solid Phase Transition Underlying Pathological Huntingtin Exon1 Aggregation.
    Peskett TR; Rau F; O'Driscoll J; Patani R; Lowe AR; Saibil HR
    Mol Cell; 2018 May; 70(4):588-601.e6. PubMed ID: 29754822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth-based determination and biochemical confirmation of genetic requirements for protein degradation in Saccharomyces cerevisiae.
    Watts SG; Crowder JJ; Coffey SZ; Rubenstein EM
    J Vis Exp; 2015 Feb; (96):e52428. PubMed ID: 25742191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth assays to assess polyglutamine toxicity in yeast.
    Duennwald ML
    J Vis Exp; 2012 Mar; (61):e3461. PubMed ID: 22415521
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.